The statistical quality of trial-based economic evaluations is often suboptimal, while a comprehensive overview of available statistical methods is lacking. Therefore, this review summarized and critically appraised available statistical methods for trial-based economic evaluations. A literature search was performed to identify studies on statistical methods for dealing with baseline imbalances, skewed costs and/or effects, correlated costs and effects, clustered data, longitudinal data, missing data and censoring in trial-based economic evaluations. Data was extracted on the statistical methods described, their advantages, disadvantages, relative performance and recommendations of the study. Sixty-eight studies were included. Of them, 27 (...
OBJECTIVES: The aim of this study was to assess the performance and impact of multilevel modelling (...
INTRODUCTION: The best data for cost-effectiveness analyses (CEAs) of group-level interventions ofte...
This article investigates the way in which the presence of censored cost data in clinical trials sho...
The statistical quality of trial-based economic evaluations is often suboptimal, while a comprehensi...
BACKGROUND: Baseline imbalances, skewed costs, the correlation between costs and effects, and missin...
Due to high and rising healthcare costs in combination with budget constraints and rising demands fo...
Introduction: The statistical quality of many trial-based economic evaluations is poor. When conduct...
The past two decades have seen an increasing use of statistical methods to support economic evaluati...
Economic evaluation provides a means of allocating finite healthcare resources in an efficient manne...
Many cost-effectiveness analyses (CEAs) use data from observational studies. Statistical methods can...
It is commonly suggested that there are two com-peting approaches to the economic evaluation of heal...
Although economic evaluations have been performed alongside factorial trials, there seems to be limi...
Objective: The objectives of this article are first to give an overview of the risks of bias in tria...
Increasing numbers of economic evaluations are conducted alongside randomised controlled trials. Suc...
Trial-based economic evaluations are an important aspect of health technology assessment. The availa...
OBJECTIVES: The aim of this study was to assess the performance and impact of multilevel modelling (...
INTRODUCTION: The best data for cost-effectiveness analyses (CEAs) of group-level interventions ofte...
This article investigates the way in which the presence of censored cost data in clinical trials sho...
The statistical quality of trial-based economic evaluations is often suboptimal, while a comprehensi...
BACKGROUND: Baseline imbalances, skewed costs, the correlation between costs and effects, and missin...
Due to high and rising healthcare costs in combination with budget constraints and rising demands fo...
Introduction: The statistical quality of many trial-based economic evaluations is poor. When conduct...
The past two decades have seen an increasing use of statistical methods to support economic evaluati...
Economic evaluation provides a means of allocating finite healthcare resources in an efficient manne...
Many cost-effectiveness analyses (CEAs) use data from observational studies. Statistical methods can...
It is commonly suggested that there are two com-peting approaches to the economic evaluation of heal...
Although economic evaluations have been performed alongside factorial trials, there seems to be limi...
Objective: The objectives of this article are first to give an overview of the risks of bias in tria...
Increasing numbers of economic evaluations are conducted alongside randomised controlled trials. Suc...
Trial-based economic evaluations are an important aspect of health technology assessment. The availa...
OBJECTIVES: The aim of this study was to assess the performance and impact of multilevel modelling (...
INTRODUCTION: The best data for cost-effectiveness analyses (CEAs) of group-level interventions ofte...
This article investigates the way in which the presence of censored cost data in clinical trials sho...